Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Chasing amylin: Must-have obesity target key to Roche-Zealand deal

Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target

March 12, 2025 9:51 PM UTC

The temperature just went up a few more degrees for obesity’s hottest target now that Roche is spending nearly $1.7 billion up front to license half of the U.S. and European rights to Zealand Pharma’s amylin agonist petrelintide. The financials are big, but the most important consideration for the Danish biotech in the hyper-competitive bidding process was gaining a partner committed to investing in the opportunity — including manufacturing — to make the obesity programs a commercial success.

Amylin has quickly become a must-have target for any pharma with long-term ambitions to compete with obesity leaders Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY). Roche (SIX:ROG; OTCQX:RHHBY) signaled as much today in its deal with Zealand Pharma A/S (CSE:ZEAL), through which the Swiss pharma gained rights to amylin agonist petrelintide...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Roche

Zealand Pharma A/S

BCIQ Target Profiles

Amylin receptor